Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Investor Presentation (May 2024)
34 slides from Atomo Diagnostics's investor presentation, May 2024
Slide 1: Atomo Diagnostics: Empowering Healthcare Consumers
ATOMO DIAGNOSTICS EMPOWERING HEALTHCARE CONSUMERS MAY 2024
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on other written or oral communications transmitted or otherwise made available to the information available as at the date of this presentation. The information in this recipient in connection with the oppor
Slide 3: Presenter Biography
PRESENTER BIOGRAPHY John Kelly - Managing Director & CEO Successful development and commercialisation of innovative medical products delivering unmatched user acceptance and performance over the last 25 years In-depth and long-lasting management, product development and commercialisation experience
Slide 4: Why Atomo?
WHY ATOMO? Atomo is a highly differentiated commercial-stage rapid test platform business, with global sales through multiple routes to market Technologically proven and commercialised platforms adressing an expanding rapid-testing market driven by industry and consumer health SEXUAL tailwinds in a
Slide 5: Favourable Market Landscape
FAVOURABLE MARKET LANDSCAPE Expansion of decentralised and at-home diagnostics as the market demands reduced burden on healthcare infrastructure and improved convenience for patients and consumers Global point-of-care diagnostics market to exceed US$75bn by 2030 1 70% of healthcare decisions are Glo
Slide 6: Transformative Innovation
TRANSFORMATIVE INNOVATION Issues with Standard Multi-Component Test Kits Advantages of Atomo Devices Complex Accurate Multiple components Easy to use Multiple user steps Correct volume of blood and reagent Convoluted workflow Seamless delivery to test strip High error rates: 10%+ by professionals, 3
Slide 7: Atomo Platform Driving Adoption of Rapid Testing
ATOMO PLATFORM DRIVING ADOPTION OF RAPID TESTING EASY TO USE Simple to use products providing reliability and usability in decentralised settings BUFFER DELIVERY DELIVERY Greater than 90% 100% reduction in reduction in buffer delivery blood delivery errors by Pascal errors by Pascal device device SP
Slide 8: Atomo Platforms
TECHNOLOGY PORTFOLIO ATOMO PLATFORMS Integrated Lancet Integrated Blood Collection Integrated Buffer Delivery Dual Test Strip LF Strip Compatibility GALILEO PASCAL ELION FLEMING CURIE (Swab-Based) ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 7
Slide 9: Blood Testing Solutions
45° IQ2 BLOOD TESTING SOLUTIONS 360° Atomo’s solutions offer improved performance and best in-class usability in point-of-care and self-testing Built-In Safety Lancet Eliminates the risk of hazardous sharps injuries by locking the 70° needle inside the device after use Accurate Blood Collection Bloo
Slide 10: Swab Testing Solutions
SWAB TESTING SOLUTIONS The Atomo Curie Platform utilises Atomo’s existing core IP and know-how to improve usability and performance of 360° swab-based rapid tests Compatible With Existing Swab-Based LF Strip Tests IQ2 Compatible with existing rapid test cassettes and swabs (nasal, nasopharyngeal, th
Slide 11: Product Registrations
PRODUCT REGISTRATIONS 8 HIV Self Test | US$4bn (2026) WHO PQ | LMIC CE Mark | UK & Europe TGA | Australia 18 Pregnancy Test | US$2.1bn (2026) CE Mark | UK & Europe ANVISA | Brazil 7 FebriDx | US$5.2bn (2026) FDA (510k) CE Mark | UK & Europe TGA | Australia Health Canada | Canada COVID-19 Antibody Te
Slide 12: Commercialisation Strategy: Growing and More Balanced Future
COMMERCIALISATION STRATEGY GROWING AND Atomo has developed user friendly platforms that support a MORE BALANCED FUTURE broad range of diagnostic applications and technologies, REVENUE CHANNELS enabling the company to generate revenues from a number of commercial channels 5% 10% Finished Goods | Supp
Slide 13: OEM
SEXUAL HEALTH WOMEN’S OEM HEALTH ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 14: Commercialisation Pipeline by Platform
COMMERCIALISATION PIPELINE BY PLATFORM Atomo’s lateral flow platforms have been developed to provide IN FEASIBILITY DEVELOPMENT COMMERCIALISED best in class usability and performance for blood and swab samples Pascal - Commercialised and Supplied to Customers PASCAL NG Biotech | UK & Europe Lumos Di
Slide 15: Commercialisation Pipeline by Application
COMMERCIALISATION PIPELINE BY APPLICATION IN FEASIBILITY DEVELOPMENT COMMERCIALISED Sexual Health 8 HIV | US$4bn (2026) HIV 15 Syphilis | US$1.4bn (2026) 16 Chlamydia US$1.8bn (2026) | Gonorrhoea (Similar Market Size to PREGNANCY Chlamydia) IRON DEFICIENCY Women’s Health 18 Pregnancy | US$2.1bn (202
Slide 16: OEM Customers
OEM CUSTOMERS NEW CUSTOMERS Lumos Diagnostics is a US company specialising NG Biotech is a French diagnostics company Atomo is working on a in rapid, cost-effective point-of-care test solutions focusing on the development and manufacture of number of development novel in-vitro diagnostics products f
Slide 17: Sexual Health
SEXUAL HEALTH WOMEN’S OEM HEALTH ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 18: HIV Market Opportunities
HIV MARKET OPPORTUNITIES The HIV diagnostics market value is expected to grow to 8 US$4bn by 2026 with a CAGR of 7.9% HIV self-testing is expected to grow to US$531m by 2026 at a CAGR of 30%. This very high growth rate is driven by convenience and privacy offered by self-testing kits as well as grow
Slide 19: Atomo's HIV Business
ATOMO’S HIV BUSINESS Registered in many countries, with more than half a million tests ordered in H2 FY24 UK, Europe & Colombia Developing Markets Australia Increasing adoption of consumer WHO estimates HIV self-testing Atomo HIV Self Test is the only self-test through mainstream retail markets in L
Slide 20: Other Sexual Health Market Opportunities
OTHER SEXUAL HEALTH MARKET OPPORTUNITIES Syphilis (Blood-Based) Substantial increase in Syphilis cases around the world, with ~7 million new cases of Syphilis globally in 2020 according to WHO data 14 Syphilis testing market is expected to be worth around US$1.4bn by 2026, growing at a CAGR of 5.6%
Slide 21: Women's Health
SEXUAL HEALTH WOMEN’S HEALTH OEM ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 22: Pregnancy Market Opportunities
PREGNANCY MARKET OPPORTUNITIES What’s driving the blood-based pregnancy market The pregnancy hormone hCG typically appears in blood earlier than urine, making blood ideal for early detection Unlike urine tests, blood tests are reliable any time of day 17 Over 20m pregnancy tests are sold annually in
Slide 23: Women's Health Market Opportunities
WOMEN’S HEALTH MARKET OPPORTUNITIES Iron Deficiency (Ferritin) The global iron deficiency/anaemia testing market is 19 expected to grow to ~US$776m by 2026 , providing significant demand for rapid testing to support treamtent WHO research suggests iron deficiency affects 30% of all women, rising to
Slide 24: Financial Summary
FINANCIAL SUMMARY Well positioned for profitability with no need for significant CapEx to fund future growth Revenue (Excluding COVID) Gross Profit (Excluding COVID) 2.5 1.0 50% 45% 2.0 0.8 40% A$000’000 35% 1.5 0.6 30% 25% 1.0 0.4 20% 15% 0.5 0.2 10% 5% 0% H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 H1
Slide 25: Financial Summary (2)
FINANCIAL SUMMARY (2) Operating Expenditure* Rolling 12 Month EBITDA 6.0 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 0.0 5.0 (0.2) (0.4) 4.0 (0.6) A$000’000 A$000’000 (0.8) 3.0 (1.0) (1.2) 2.0 (1.4) (1.6) 1.0 (1.8) 0 (2.0) H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 OpEx continues to reduce materially having come d
Slide 26: Goals
GOALS Near-Term (12 Months) Finalise execution of a funded development program for new platforms Secure new OEM customers for Pascal blood-based platform Progress US strategic partner discussions to support market entry into CLIA and OTC channels Continue restructuring of Atomo’s operational footpri
Slide 27: Appendix
APPENDIX
Slide 28: Intellectual Property Portfolio
INTELLECTUAL PROPERTY PORTFOLIO ATOMO PATENTS Family 1: Diagnostic System PCT/AU2011/000315 Family 2: Sampling Assembly PCT/AU2011/001321 Family 3: Fluid Control in Integrated Testing Devices PCT/IB2014/066219 Family 4: Integrated Fluid Module and Test Device PCT/AU2016/051134 Family 5: Integrated B
Slide 29: Infrastructure & Capabilities
INFRASTRUCTURE & CAPABILITIES Design, development and prototyping capability based in Sydney, Australia Atomo’s certified manufacturing facility in Cape Town, South Africa, has been audited by WHO, TGA and BSI (ISO 13485:2016), SAHPRA (South African Health Product Regulatory Authority) Increased dec
Slide 30: Organisational Chart
ORGANISATIONAL CHART Managing Upscaling Resources Director Phase 1 - FY25 Product Development Executive Resource x 3 Assistant Chief Operations Program Director Officer Phase 2 - FY26 Project Manager QA Engineer x 2 Senior Product People Experience Head of QA Finance BDM Manager Manager & RA Manager
Slide 31: Executive Team & Board of Directors
EXECUTIVE TEAM & BOARD OF DIRECTORS JOHN KELLY CHANDRA SUKUMAR JOHN KEITH DEBORAH J. NEFF DR. CHERI WALKER DR. PAUL KASIAN CHIEF EXECUTIVE OFFICER CHIEF OPERATING OFFICER NON-EXECUTIVE CHAIR NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR Before founding Atomo Chandra joined Ato
Slide 32: Transaction Summary
TRANSACTION SUMMARY ISSUER Atomo Diagnostics Limited TICKER/LISTING AT1 | Australian Stock Exchange STRUCTURE/TIME USE OF PROCEEDS JOINT BOOKRUNNERS INDICATIVE TIMETABLE This announcement was authorised by the Managing Director and CEO 1 The above timetable is indicative only and subject to change.
Slide 33: Sources
SOURCES 1 BusinessWire, 2024, Global Point of Care Testing (POCT) Market Report 2023-2030: Continued Expansion of Point of Care Including Self Testing Fueling Growth - ResearchAndMarkets.com, BusinessWire, viewed 14 April 2024, <https://www.businesswire.com/news/home/20240115203040/en/Global-Point-o
Slide 34: Sources
SOURCES 13 Department of Health and Aged Care, 2024. Budget 2024-2025: Ensuring all Australians get the health care they need, Australian Government, viewed 15 May 2024, <https://www.health.gov.au/resources/publications/budget-2024-25-ensuring-all-australians-get-the-health-care-they-need?language=e